Sentences with phrase «neck cancer patients»

Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial

This page features information on head and neck cancer and immunotherapy clinical trials for head and neck cancer patients, and highlights the Cancer Research Institute's role in working to bring effective immune - based cancer treatments to head and neck cancer patients.

After doing a genetic epidemiology research project at McGill, looking at whether family members of head and neck cancer patients had an increased risk of the disease (and finding the topic fascinating), she went to the University of Washington (U.W.) in Seattle to earn a master's degree in epidemiology.

More importantly, Papagerakis notes, head and neck cancer patients are already taking these medications.

«To our surprise, we saw a number of head and neck cancer patients who tested positive for the hepatitis C virus.

These kinds of sensors could also track the recovery of neck cancer patients, who commonly develop swallowing and speaking problems caused by radiation therapy and surgery, Rogers says.

Head and neck cancer patients were once primarily older heavy smokers and drinkers.

«These exciting results indicate that there is a new standard of care option for a population of head and neck cancer patients with no other treatment options,» said the trial's international co-chair Robert Ferris, M.D., Ph.D., UPMC Endowed Professor, and chief of the Division of Head and Neck Surgery and co-leader of the Cancer Immunology Program at UPCI.

Not exact matches

She and other colleagues first noticed an odd shift in patient profiles in the late 1990s: younger men were showing up in her clinic, often with no significant history of smoking or heavy drinking, which are risk factors for head and neck cancers.

The study, was reported Feb 13 to the 5th International Conference on Innovative Approaches in Head and Neck Oncology (ICHNO) will reduce significantly the number of HNSCC patients who currently undergo selective neck dissection (SND), a procedure which involves removing a group of lymph nodes from the neck in order to try to eradicate those which may have been reached by the cancer.

«New radiotracer helps avoid neck dissection in patients with early head and neck cancer.»

A new tracer can enable surgeons to make an accurate identification of the sentinel node — the lymph node to which cancer spreads first — and hence spare patients the post-operative complications that may be linked to the removal of a group of lymph nodes in the neck.

The highest prevalence was found among patients with breast cancer (42 %) and head and neck cancer (41 %), followed by malignant melanoma (39 %).

Dr. Islam saw this phenomenon occur in cell culture and in some samples from patients with head and neck cancers.

• Speech language pathologists work with many types of patients including those who have cochlear implantation surgery, suffer from a voice disorder or during rehabilitation following treatment for head and neck cancer.

Low saliva production also is a devastating problem for thousands of patients who have had radiation treatment for head and neck cancer, as well as about 50 percent of older Americans whose medications can cause dry mouth, also known as xerostomia.

Silent Stories explores the strength of cancer patients who underwent radiotherapy to treat head or neck cancer.

Results of an initial study of tumors from patients with lung cancer or head and neck cancer suggest that the widespread acquired resistance to immunotherapy drugs known as checkpoint inhibitors may be due to the elimination of certain genetic mutations needed to enable the immune system to recognize and attack malignant cells.

To investigate why checkpoint inhibitors so often stop working, Velculescu; Valsamo Anagnostou, M.D., Ph.D., instructor of oncology at the Johns Hopkins University School of Medicine; Kellie N. Smith, Ph.D., a cancer immunology research associate at the Johns Hopkins University School of Medicine; and their colleagues at the Bloomberg ~ Kimmel Institute for Cancer Immunotherapy studied tumors of four patients with non-small cell lung cancer and one patient with head and neck cancer who developed resistance to two different checkpoint inhibitors: a drug called nivolumab that uses an antibody called anti-PD-1, or nivolumab used alone or in combination with a second drug called ipilimumab, which uses an antibody called anti-cancer immunology research associate at the Johns Hopkins University School of Medicine; and their colleagues at the Bloomberg ~ Kimmel Institute for Cancer Immunotherapy studied tumors of four patients with non-small cell lung cancer and one patient with head and neck cancer who developed resistance to two different checkpoint inhibitors: a drug called nivolumab that uses an antibody called anti-PD-1, or nivolumab used alone or in combination with a second drug called ipilimumab, which uses an antibody called anti-Cancer Immunotherapy studied tumors of four patients with non-small cell lung cancer and one patient with head and neck cancer who developed resistance to two different checkpoint inhibitors: a drug called nivolumab that uses an antibody called anti-PD-1, or nivolumab used alone or in combination with a second drug called ipilimumab, which uses an antibody called anti-cancer and one patient with head and neck cancer who developed resistance to two different checkpoint inhibitors: a drug called nivolumab that uses an antibody called anti-PD-1, or nivolumab used alone or in combination with a second drug called ipilimumab, which uses an antibody called anti-cancer who developed resistance to two different checkpoint inhibitors: a drug called nivolumab that uses an antibody called anti-PD-1, or nivolumab used alone or in combination with a second drug called ipilimumab, which uses an antibody called anti-CTLA4.

Patients with HCV - positive head and neck cancers were more likely to also test positive for HPV.

Having only people with head and neck cancers in the study eliminates the variability of a group suffering from different forms of the disease, but it also eliminates information about whether patients with other forms of cancer would show the same results.

«With head and neck cancer, we often clear patients of cancer only to see it come back with deadly consequences a few years later,» said lead author Julie Bauman, M.D., M.P.H., co-director of the UPMC Head and Neck Cancer Center of Excelcancer, we often clear patients of cancer only to see it come back with deadly consequences a few years later,» said lead author Julie Bauman, M.D., M.P.H., co-director of the UPMC Head and Neck Cancer Center of Excelcancer only to see it come back with deadly consequences a few years later,» said lead author Julie Bauman, M.D., M.P.H., co-director of the UPMC Head and Neck Cancer Center of ExcelCancer Center of Excellence.

«This study, one of only a few large studies to have follow - up beyond five years, demonstrates that patients who have head and neck cancers and who are being treated with radiation therapy alone have improved local - regional control and no increase in late toxicity when radiation therapy is delivered twice a day in two smaller doses which we call hyperfractionation,» said Jonathan J. Beitler, MD, MBA, FASTRO, lead author of the study and professor of radiation oncology, otolaryngology and hematology / medical oncology at the Winship Cancer Institute of Emory University School of Medicine in Atlanta.

Patients with head and neck cancer who used antacid medicines to control acid reflux had better overall survival, according to a new study from the University of Michigan Comprehensive Cancer Ccancer who used antacid medicines to control acid reflux had better overall survival, according to a new study from the University of Michigan Comprehensive Cancer CCancer Center.

Patients with head and neck cancer seldom survive for longer than six months to one year when treated with chemotherapy alone.

THREE patients with incurable neck and head cancer have survived for three years after being treated with a combination of chemotherapy and a cold virus that has been modified to attack tumours.

Between 32 % to 75 % of patients diagnosed with head and neck cancers cancer have surgery to remove the tumour as part of their primary cancer treatment.

Interestingly, Myh9 is also mutated in human head and neck cancers, and low expression of myosin IIa correlates with poor prognosis for the patient,» says Fuchs.

Between 8 % and 61 % of patients diagnosed with head and neck cancers have chemotherapy as part of their primary cancer treatment.

Our multidisciplinary staff pursues an integrated approach to treating head and neck cancers by combining the latest research findings with outstanding patient care.

Ongoing studies suggest it may benefit patients with many different cancers, including lung, brain, head and neck, stomach, and kidney cancers.

Through CRI's Clinical Accelerator program, two new checkpoint inhibitor drugs, MEDI4736 (anti-PD-L1) and tremelimumab (anti-CTLA-4), are being tested in a phase I trial for patients with six different cancer types, including colorectal cancer, cervical cancer, head and neck cancer, kidney cancer, lung cancer, and ovarian cancer.

The drug or drug combination used depends on the type and stage of head and neck cancer, previous treatments used, the patient's health and overall treatment goals.

Since then, however, other researchers have observed the same gene fusion in a percentage of lung, esophageal, breast, head and neck, cervical, and bladder cancers, affecting tens of thousands of cancer patients overall.

Radiation therapy is a lifesaver for patients with head and neck cancer, but the treatment takes a toll on the salivary gland.

In a recent multi-institutional phase II trial of Onyx - 015 led by investigators at University of Texas M.D. Anderson Cancer Center, 30 patients with advanced head and neck cancer, most of whom had failed surgery or radiation therapy, were trCancer Center, 30 patients with advanced head and neck cancer, most of whom had failed surgery or radiation therapy, were trcancer, most of whom had failed surgery or radiation therapy, were treated.

At the Harold C. Simmons Comprehensive Cancer Center, our support services for head and neck cancer focus on rehabilitation, survivorship, and psychology to help patients and their families through the cancer joCancer Center, our support services for head and neck cancer focus on rehabilitation, survivorship, and psychology to help patients and their families through the cancer jocancer focus on rehabilitation, survivorship, and psychology to help patients and their families through the cancer jocancer journey.

Dr. Eduardo Méndez has received a five - year, $ 2.2 million grant from the National Institutes of Health to develop the first targeted therapy that they hope will be effective for most patients with head and neck cancers.

Working with colleagues at the University of Chicago, our experts created a new combination chemotherapy and radiation therapy treatment regimen that helps some patients with advanced head and neck cancer avoid major surgery.

For many patients with cancers of the head and neck, the symptoms are all too common.

Head and neck cancer can affect a patient's quality of life, appearance, and self - esteem.

For this purpose, at least 30 different cell lines derived from biopsies (HNSCC — head and neck cancer — patients) wil be collected and grown in culture to esstablish cell lines.

An estimated 55,000 patients are diagnosed each year with head and neck cancers, which includes cancers of the mouth and throat.

A systematic review of observational studies suggested that smoking cessation after bladder cancer is beneficial, but owing to confounding and methodological concerns of included studies no firm conclusions could be drawn.30 Some observational studies have also shown an association between smoking cessation in patients with head and neck cancer and reduced risk of disease progression and mortality, but the absence of a systematic review and meta - analysis means that the strength of this association is uncertain.31 32 33

The researchers treated 76 patients between 1993 and 1996 with intensive therapy for advanced cancers of the head and neck.

We see patients with all types of head and neck cancers, including:

Several trials of adoptive T cell transfer techniques are currently under way for patients with head and neck cancer, including:

The five - year survival rate of patients with head and neck cancer is about 60 %.

Based on these promising results, an additional 110 patients with advanced head and neck cancer are being recruited to the study.

During the study, the researchers tracked the pre-and-post treatment diets and ultimate health outcomes of more than 400 cancer patients for an average of 26 months after they were first diagnosed and treated for squamous - cell carcinoma of the head or neck.